Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total value of $1,284,800.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at $49,322,187.20. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $70.21, for a total value of $702,100.00.
• On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $1,393,800.00.
• On Thursday, February 5th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $78.64, for a total transaction of $786,400.00.
• On Tuesday, February 3rd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $76.12, for a total transaction of $1,522,400.00.

Halozyme Therapeutics Trading Down 1.4%

Shares of HALO traded down $0.91 during mid-day trading on Thursday, hitting $64.49. The company had a trading volume of 1,523,428 shares, compared to its average volume of 1,873,950. Halozyme Therapeutics, Inc. has a 1-year low of $47.50 and a 1-year high of $82.22. The business’s 50-day simple moving average is $70.17 and its 200-day simple moving average is $69.50. The stock has a market cap of $7.64 billion, a PE ratio of 25.90, a P/E/G ratio of 0.26 and a beta of 1.03. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business’s revenue for the quarter was up 51.6% on a year-over-year basis. During the same period last year, the company posted $1.26 EPS. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently weighed in on HALO shares. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. The Goldman Sachs Group restated a “sell” rating and issued a $56.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, December 4th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Finally, TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $78.56.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of large investors have recently modified their holdings of the stock. Measured Wealth Private Client Group LLC boosted its holdings in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the period. Abel Hall LLC raised its stake in shares of Halozyme Therapeutics by 4.2% during the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 129 shares during the period. StoneX Group Inc. raised its stake in shares of Halozyme Therapeutics by 3.8% during the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 132 shares during the period. Moran Wealth Management LLC lifted its position in shares of Halozyme Therapeutics by 0.4% during the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock worth $2,396,000 after purchasing an additional 151 shares in the last quarter. Finally, Campbell Newman Asset Management Inc. lifted its position in shares of Halozyme Therapeutics by 0.4% during the third quarter. Campbell Newman Asset Management Inc. now owns 36,878 shares of the biopharmaceutical company’s stock worth $2,705,000 after purchasing an additional 153 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.